Viridian Shares Slip as Amgen's TEPEZZA Posts Strong Data
Shares of Viridian Therapeutics (VRDN) dropped sharply Monday, after new data for Amgen (AMGN)'s TEPEZZA highlighted robust efficacy in treating thyroid eye disease (TED) — intensifying competitive concerns for Viridian's rival drug candidate, elegrobart.
Benzinga reports that the Phase 3 TEPEZZA OBI trial met its primary endpoint, with a statistically significant 77% proptosis (bulging eyes) response rate over 24 weeks, and an average proptosis reduction of -3.17. In contrast, Viridian’s recently reported REVEAL-1 Phase 3 trial achieved responder rates of 54% (every 4 weeks) and 63% (every 8 weeks) for elegrobart, compared to 18% for placebo. While elegrobart showed statistically significant effects, its placebo-adjusted proptosis responder rates of 36% and 45% fell short of the 51%-73% range investors had hoped for.
Data Highlights Heightened Competition
With Amgen’s TEPEZZA maintaining a high efficacy bar, analysts and investors are scrutinizing whether Viridian’s elegrobart can offer meaningful differentiation—either through dosing convenience or clinical outcomes. Benzinga specifically notes that 'the stock fell on weaker efficacy relative to peers, which could raise investor concerns about commercial viability.'
Market Reaction
Viridian Therapeutics (VRDN) shares were down 22.03% at $14.69 on Monday, reflecting the market’s concerns over elegrobart’s positioning next to TEPEZZA’s strong clinical showing. In biotech, perceived disadvantages in late-stage trial results can put severe pressure on earlier-stage challengers before any direct clinical failure occurs.
Next Steps for Elegrobart
The focus now for Viridian is whether upcoming data or stratified patient benefits—such as dosing frequency or specific TED subtypes—can position elegrobart as a commercially viable alternative. Topline data from the ongoing REVEAL-2 chronic TED study is expected in Q2 2026, with a Biologics License Application targeted for early 2027.
- Key catalyst: Additional clinical readouts for elegrobart, especially from REVEAL-2, will be critical for sentiment.
- Peer data: Ongoing performance and market updates for TEPEZZA will influence the competitive narrative.
- Analyst reaction: Any changes in analyst ratings or commentary may further shift sentiment around Viridian.
Stocks365 Take
Monday’s slide reflects the market’s rapid repricing of competitive risk when a late-stage rival reports compelling data. At this stage, Viridian’s path forward depends on both future clinical milestones and demonstrating clear differentiation. Our view: exercise caution on new long positions in VRDN until further data clarifies how elegrobart compares to TEPEZZA. For those already positioned, monitor stabilization and corporate updates closely. Amgen’s TEPEZZA remains the clinical benchmark in TED; Viridian must now prove its case to reestablish market confidence.
